Increased Weight Loss With the Combination of Levoketoconazole and Semaglutide in a Patient With Mild Hypercortisolism
Abstract
BACKGROUND/OBJECTIVE: A patient with obesity, anxiety, depression, and hyperandrogenism, diagnosed with mild hypercortisolism of unknown etiology, had increased weight loss with the combination of levoketoconazole and semaglutide.
CASE REPORT: A 21-year-old female with a history of polycystic ovary syndrome, anxiety, depression, and obesity presented with irregular menstrual cycles, acne, and excess body hair. Her weight at initial visit was 275 lbs, with physical examination showing moon facies, dorsocervical fat pad, supraclavicular fat pad, and abdominal striae. Medications included sertraline 100 mg daily and metformin 500 mg daily, which was increased; spironolactone was added, and Ozempic 0.25 mg subcutaneously weekly was started and titrated up to 1 mg subcutaneously weekly. The patient lost 42 lbs with Ozempic but plateaued. A dexamethasone suppression test showed a non-suppressed adrenocorticotropic hormone 10 (reference: 7.2-63.3) and morning cortisol 6.7 ng/dL (reference: <1.8 ng/dL). The 24-hour urinary free cortisol was high normal 42 μg per 24 hours (reference: 6-42 μg per 24 hours) with a negative magnetic resonance imaging and computed tomography scan for pituitary or adrenal tumors. A diagnosis of hypercortisolism of unknown origin was made, with the decision to treat with levoketoconazole. The patient lost an additional 47 lbs, resulting in a total weight loss of 89 lbs while on levoketoconazole and semaglutide, and the cortisol levels normalized.…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.